Exceptional research belongs in the community.
Behind every trial is a physician who knows the patient's name. That's where we start.
The science is extraordinary.
The delivery model is broken.
Breakthroughs are arriving faster than ever. The system that carries them to patients hasn't kept up.
Clinical research is concentrated in major metro areas, so most patients never reach the trials that could help them.
85% of studies start or finish late, and sponsors plan around failure as a given, while patients far from those centers never hear about the trial that could have changed their outcome.
PhaseWell exists to close that gap: exceptional investigators, community-rooted sites, and the infrastructure to make commitments mean something.
That's why we exist.
The future we're building.
Not just where we're going, where we refuse to stop until we arrive. For patients, for sponsors, for the science.
A patient in their own community knows a trial exists, and can join one.
Community physicians bridge the gap between breakthrough and bedside. A patient doesn't stumble onto a trial. Their own doctor tells them about it.
Sponsors get what they were promised.
Timelines hold. Enrollment targets are met. A commitment means something, because we only make one when we know we can keep it. That's not an improvement. It's a different relationship entirely.
Every patient has a physician in their corner.
The physician or advanced practice provider (APP) who explains the trial is the one who sees the patient through it. That relationship, built at the moment of consent, drives retention, trust, and outcomes that matter.
Research sites exist for the patient in front of them.
Patients enroll asking can this help me, and stay through altruism when it can't. A site built for research holds both. No competing priorities, no enrollment as an afterthought.
Every patient who comes to PhaseWell has chosen to take a leap of faith. We take that seriously. The physician relationship, the community trust, the commitment to delivering, none of that is incidental. It is the whole point.
